Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Go back to Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy| Pfizer Inc. (NYSE: PFE) | Delayed: 28.37 +0.09 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.28 | 52 Week High | $37.39 | |||
| Open | $28.42 | 52 Week Low | $28.25 | |||
| Day High | $28.50 | P/E | 17.19 | |||
| Day Low | $28.28 | EPS | $1.65 | |||
| Volume | 6,124,763 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 28.37 +0.09 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.28 | 52 Week High | $37.39 | |||
| Open | $28.42 | 52 Week Low | $28.25 | |||
| Day High | $28.50 | P/E | 17.19 | |||
| Day Low | $28.28 | EPS | $1.65 | |||
| Volume | 6,124,763 | |||||
| Sangamo Biosciences, Inc. (NASDAQ: SGMO) | Delayed: 0.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.18 | 52 Week High | $9.91 | |||
| Open | $0.18 | 52 Week Low | $3.10 | |||
| Day High | $0.18 | P/E | N/A | |||
| Day Low | $0.18 | EPS | $-0.48 | |||
| Volume | 5,000 | |||||



